Literature DB >> 23429380

HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.

Charlotte Charpentier1, Ricardo Camacho, Jean Ruelle, Rolf Kaiser, Josef Eberle, Lutz Gürtler, Alejandro Pironti, Martin Stürmer, Françoise Brun-Vézinet, Diane Descamps, Martin Obermeier.   

Abstract

Considering human immunodeficiency virus type 2 (HIV-2) phenotypic data and experience from HIV type 1 and from the follow-up of HIV-2-infected patients, a panel of European experts voted on a rule set for interpretation of mutations in HIV-2 protease, reverse transcriptase, and integrase and an automated tool for HIV-2 drug resistance analyses freely available on the Internet (http://www.hiv-grade.de).

Entities:  

Keywords:  HIV-2; Internet tool; drug-resistance rules

Mesh：

Substances：

Year:  2013        PMID： 23429380     DOI： 10.1093/cid/cit104

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

2.  Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.

Authors:  Boris K Tchounga; Bo L Hønge; Serge P Eholie; Patrick A Coffie; Sanne Jespersen; Christian Wejse; François Dabis; Gottlieb S Geoffrey; Didier K Ekouevi
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

3.  Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.

Authors:  Ilona P Deuzing; Charlotte Charpentier; David W Wright; Sophie Matheron; Jack Paton; Dineke Frentz; David A van de Vijver; Peter V Coveney; Diane Descamps; Charles A B Boucher; Nancy Beerens
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

4.  Genotypic resistance profiles of HIV-2-treated patients in West Africa.

Authors:  Charlotte Charpentier; Serge Eholié; Xavier Anglaret; Mélanie Bertine; Christine Rouzioux; Véronique Avettand-Fenoël; Eugène Messou; Albert Minga; Florence Damond; Jean-Christophe Plantier; François Dabis; Gilles Peytavin; Françoise Brun-Vézinet; Didier K Ekouevi
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

5.  HIV-2 Drug Resistance Genotyping from Dried Blood Spots.

Authors:  Dana N Raugi; Robert S Nixon; Sally Leong; Khadim Faye; Jean Phillipe Diatta; Fatima Sall; Robert A Smith; ElHadji Ibrahima Sall; Jean Jacques Malomar; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 5.948

Review 6.  Mortality and survival patterns of people living with HIV-2.

Authors:  Boris Tchounga; Didier K Ekouevi; Eric Balestre; François Dabis
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

7.  A modular system to evaluate the efficacy of protease inhibitors against HIV-2.

Authors:  Mohamed Mahdi; Krisztina Matúz; Ferenc Tóth; József Tőzsér
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

8.  A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.

Authors:  Matthias Döring; Pedro Borrego; Joachim Büch; Andreia Martins; Georg Friedrich; Ricardo Jorge Camacho; Josef Eberle; Rolf Kaiser; Thomas Lengauer; Nuno Taveira; Nico Pfeifer
Journal:  Retrovirology       Date:  2016-12-20       Impact factor: 4.602

9.  First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Authors:  Sophie Matheron; Diane Descamps; Sebastien Gallien; Amel Besseghir; Pierre Sellier; Laurent Blum; Emmanuel Mortier; Charlotte Charpentier; Roland Tubiana; Florence Damond; Gilles Peytavin; Diane Ponscarme; Fideline Collin; Francoise Brun-Vezinet; Genevieve Chene
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

10.  Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.

Authors:  Mohamed Mahdi; Zsófia Szojka; János András Mótyán; József Tőzsér
Journal:  Viruses       Date:  2015-11-27       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.